[Photodynamic therapy and urothelial carcinoma]

Bull Cancer. 2011 Jul;98(7):769-78. doi: 10.1684/bdc.2011.1389.
[Article in French]

Abstract

Purpose: Photodynamic therapy (PDT) is an innovative therapeutic modality in urologic oncology.

Material and methods: We reviewed the current literature on principles and modalities of PDT in urothelial and penile oncology.

Results: PDT has been tested for the treatment recurrent superficial bladder tumors and in situ carcinoma. Carcinologic efficacy has been observed with first generation photosensitizer. The lack of selectivity for tumoral cells was responsible of serious adverse events. Development of selective photosensitizers has reduced the importance of side effects. Data concerning PDT for upper urinary tract and urethra carcinoma are still limited.

Conclusion: First PDT clinical applications in urothelial oncology have shown some effectiveness at the cost of significant morbidity. The development of selective photosensitizers should help to reduce side effects.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Carcinoma in Situ / drug therapy
  • Humans
  • Photochemotherapy / adverse effects
  • Photochemotherapy / methods*
  • Photosensitizing Agents / adverse effects
  • Photosensitizing Agents / therapeutic use*
  • Ureteral Neoplasms / drug therapy
  • Urethral Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / drug therapy
  • Urologic Neoplasms / drug therapy*

Substances

  • Photosensitizing Agents